AST-120 for kidney protection after acute kidney injury
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if the drug AST-120 (Kremezin) can help protect your kidneys and slow down further kidney decline after a recent acute kidney injury. It is for people who had a moderate to severe kidney injury during a hospital stay and now have mild to moderate chronic kidney damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You had a moderate to severe acute kidney injury (stage 2 or 3) during a hospital stay, within the last 3 months.
- After leaving the hospital, your kidney function (eGFR) is between 30 and 60, which is moderate kidney damage.
- Your hospital stay for the kidney injury was no more than 1 month.
- You do not have cancer, a blood cancer, or other serious conditions like a diabetic foot or blocked urinary tract with infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether azacitidine (a medication that changes how cells read genes) can lower the risk of acute kidney injury after cardiac surgery, especially in people already at risk along the chronic kidney disease (CKD) pathway. It aims to protect kidney function during the vulnerable period after surgery.
This trial tests if taking a common antibiotic (TMP/SMX) after a kidney injury can help prevent infections after you leave the hospital. It might be an option if you had acute kidney injury during your hospital stay and are being discharged to recover at home or a rehabilitation facility.
This study tests a special type of stem cell treatment called mesenchymal stromal cells (Amimestrocel) for patients with acute kidney injury. The goal is to see if this treatment can help kidneys recover better than standard care.
This trial tests ways to protect the kidneys in intensive-care patients who have moderate or severe acute kidney injury. If you are on a ventilator or medications to support blood pressure, this study may offer extra kidney care to help prevent further damage.
This study tests whether a medicine called cilastatin can prevent kidney damage caused by certain strong medications. If you are receiving one of these medications and are at risk for kidney injury, this trial may offer protection.
This trial tests whether finerenone (a medicine that helps protect the kidneys) can improve recovery from acute kidney injury (sudden kidney failure) in hospitalized patients. Participation involves taking the study drug or a placebo while in the hospital.
Hear when a new Acute Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.